CLINDAMYCIN PALMITATE HYDROCHLORIDE

Post-LOE

clindamycin palmitate hydrochloride

Molecular Devices

ANDAORALFOR SOLUTION

Approved

Aug 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CLINDAMYCIN PALMITATE HYDROCHLORIDE (clindamycin palmitate hydrochloride) by Molecular Devices is clinical pharmacology human pharmacology absorption blood level studies comparing clindamycin palmitate hci with clindamycin hydrochloride show that both drugs reach their peak active serum levels at the same time, indicating a rapid hydrolysis of the palmitate to the clindamycin. Approved for the treatment of serious infections caused by susceptible anaerobic bacteria, the treatment of serious infections due to susceptible strains of streptococci, pneumococci and 7 more indications. First approved in 2012.

Drug data last refreshed 23h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Human Pharmacology Absorption Blood level studies comparing clindamycin palmitate HCI with clindamycin hydrochloride show that both drugs reach their peak active serum levels at the same time, indicating a rapid hydrolysis of the palmitate to the clindamycin. Serum level…

Worked on CLINDAMYCIN PALMITATE HYDROCHLORIDE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

CLINDAMYCIN PALMITATE HYDROCHLORIDE

Mechanism of Action

Indications (10)